{"entity":{"id":"electra-therapeutics","kind":"company","name":"Electra Therapeutics","aka":["Electra Therapeutics, Inc.","Electra Therapeutics Inc."],"tldr":"A US company making antibodies against SIRP proteins to remove overactive immune cells. Its lead drug is mainly for a dangerous inflammatory condition called sHLH, and it is also in an early trial for T-cell and NK-cell blood cancers that have come back.","summary":"Electra Therapeutics develops antibodies directed at signal regulatory proteins (SIRP) that it says selectively deplete activated, disease-driving immune cells. Its lead antibody, ipsoprubart (ELA026), binds SIRP-alpha and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells. It is in a registrational Phase 2/3 programme as first-line treatment for secondary haemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory condition whose largest subtype, the company says, is malignancy-associated HLH, and in a Phase 1 trial in relapsed or refractory T-cell and NK-cell malignancies (NCT07465835, recruiting since February 2026). A second antibody, ELA822, is aimed at immune-mediated diseases. The IPO prospectus states the company was incorporated in Delaware in October 2018 as a wholly owned subsidiary of Star Therapeutics. Its Form 8-K reports that the IPO closed on 21 September 2026 at $15.00 a share for gross proceeds of about $350.0 million, with the stock on the Nasdaq Global Select Market under ETRA.","asOf":"2026-11-04","links":[{"label":"SEC: Electra Therapeutics Form S-1/A, September 2026","url":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526389755/d61940ds1a.htm"},{"label":"Official website","url":"https://electra-therapeutics.com/"},{"label":"Pipeline page","url":"https://electra-therapeutics.com/pipeline/"},{"label":"Ipsoprubart page","url":"https://electra-therapeutics.com/ipsoprubart/"},{"label":"Form 8-K on IPO closing, 21 September 2026","url":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526396646/d185250d8k.htm"},{"label":"IPO prospectus (424B4)","url":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526395670/d61940d424b4.htm"},{"label":"ClinicalTrials.gov NCT07465835","url":"https://clinicaltrials.gov/study/NCT07465835"},{"label":"RA Capital portfolio entry","url":"https://www.racap.com/portfolio/electra-therapeutics"},{"label":"OrbiMed portfolio","url":"https://www.orbimed.com/portfolio/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["monoclonal-antibody"],"targets":["sirpa"],"drugs":["ipsoprubart"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cancer ids left empty: the trial condition is 'T Cell Malignancies' without a named subtype, and sHLH is not a cancer.","NCT07465835 (Phase 1, T/NK cell malignancies) and NCT05416307 (Phase 2/3, sHLH) were confirmed through the ClinicalTrials.gov v2 API; neither is a trial record in OnCo yet.","OrbiMed's portfolio page lists Electra with a first investment dated 02/09/2022; the prospectus names OrbiMed Private Investments VII as a holder with a board designee."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://electra-therapeutics.com/","ticker":"NASDAQ: ETRA","founded":2018,"stage":"public","investors":["ra-capital","orbimed"],"funding":[{"round":"IPO","year":2026,"amountUsd":350000000,"source":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526396646/d185250d8k.htm","note":"23,333,334 shares at $15.00; gross proceeds of approximately $350.0 million before underwriting discounts and expenses."}]},"route":"/companies/electra-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/"}],"drug":[{"id":"ipsoprubart","kind":"drug","name":"Ipsoprubart","route":"/drugs/ipsoprubart/"}],"company":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}],"trial":[{"id":"nct07465835","kind":"trial","name":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)","route":"/trials/nct07465835/"}]}}